Literature DB >> 22048723

The kallikrein-kinin system and oxidative stress.

Yukako Kayashima1, Oliver Smithies, Masao Kakoki.   

Abstract

PURPOSE OF REVIEW: The kallikrein-kinin system (KKS) constitutes a complex multienzyme cascade that produces several bioactive kinin peptides and their derivatives including bradykinin. In addition to the classical notion of the KKS as a potent vasodilator and a mediator of inflammatory responses, recent studies suggest a link between the KKS and oxidative stress. A number of established mouse models with altered levels of KKS components opened the way to evaluate precise functions of the KKS. Here we review recent findings on the role of the KKS in cardiovascular diseases and chronic kidney diseases, and discuss potential benefits of KKS activation in these diseases. RECENT
FINDINGS: Deletion of both B1R and B2R in a diabetic mouse model exacerbates its renal phenotypes, suggesting that the KKS exerts protective effects on diabetic nephropathy by suppressing oxidative stress, presumably via nitric oxide and prostaglandins.
SUMMARY: Accumulating evidence has highlighted the importance of the KKS as a protective system against oxidative stress and organ damage in the heart and kidney. The activation of the KKS by angiotensin I-converting enzyme inhibitors and vasopeptidase inhibitors is likely to be beneficial in senescence-associated cardiovascular diseases and chronic kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22048723      PMCID: PMC3657726          DOI: 10.1097/MNH.0b013e32834d54b1

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  45 in total

1.  Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy.

Authors:  E Villa; A Rábano; L M Ruilope; R García-Robles
Journal:  Am J Hypertens       Date:  1997-02       Impact factor: 2.689

2.  Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse.

Authors:  W Huang; Y Gallois; N Bouby; P Bruneval; D Heudes; M F Belair; J H Krege; P Meneton; M Marre; O Smithies; F Alhenc-Gelas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.

Authors:  Chao-Hung Wang; Nathalie Leung; Nathalie Lapointe; Linda Szeto; Kristine D Uffelman; Adria Giacca; Jean L Rouleau; Gary F Lewis
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

4.  Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension.

Authors:  Sukhbir S Dhamrait; John R Payne; Ping Li; Alun Jones; Iqbal S Toor; Jacqueline A Cooper; Emma Hawe; Jutta M Palmen; Peter T E Wootton; George J Miller; Steve E Humphries; Hugh E Montgomery
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

5.  Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients.

Authors:  Isabelle Maltais; Magdalena Bachvarova; Pierre Maheux; Patrice Perron; Francois Marceau; Dimcho Bachvarov
Journal:  Can J Physiol Pharmacol       Date:  2002-04       Impact factor: 2.273

6.  Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides.

Authors:  E Jaspard; L Wei; F Alhenc-Gelas
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

7.  The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia.

Authors:  K Mikrut; J Paluszak; J Kozlik; P Sosnowski; H Krauss; E Grześkowiak
Journal:  Diabetes Res Clin Pract       Date:  2001-02       Impact factor: 5.602

8.  Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Authors:  Stefan Schäfer; Hans-Ludwig Schmidts; Markus Bleich; Andreas E Busch; Wolfgang Linz
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

9.  Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor.

Authors:  Joost P Schanstra; Johan Duchene; Francoise Praddaude; Patrick Bruneval; Ivan Tack; Jacques Chevalier; Jean-Pierre Girolami; Jean-Loup Bascands
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01-30       Impact factor: 4.733

10.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.

Authors:  B Rigat; C Hubert; F Alhenc-Gelas; F Cambien; P Corvol; F Soubrier
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

View more
  17 in total

Review 1.  Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.

Authors:  Amaly Nokkari; Hadi Abou-El-Hassan; Yehia Mechref; Stefania Mondello; Mark S Kindy; Ayad A Jaffa; Firas Kobeissy
Journal:  Prog Neurobiol       Date:  2018-01-31       Impact factor: 11.685

2.  Salt-dependent inhibition of epithelial Na+ channel-mediated sodium reabsorption in the aldosterone-sensitive distal nephron by bradykinin.

Authors:  Mykola Mamenko; Oleg Zaika; Peter A Doris; Oleh Pochynyuk
Journal:  Hypertension       Date:  2012-10-01       Impact factor: 10.190

Review 3.  Kidney-lung connections in acute and chronic diseases: current perspectives.

Authors:  Luca Visconti; Domenico Santoro; Valeria Cernaro; Michele Buemi; Antonio Lacquaniti
Journal:  J Nephrol       Date:  2016-03-03       Impact factor: 3.902

Review 4.  Kidney tubules: intertubular, vascular, and glomerular cross-talk.

Authors:  David A Ferenbach; Joseph V Bonventre
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

5.  Effects of kinin B(1) and B(2) receptor antagonists on overactive urinary bladder syndrome induced by spinal cord injury in rats.

Authors:  Stefânia Forner; Edinéia L Andrade; Alessandra C Martini; Allisson F Bento; Rodrigo Medeiros; Janice Koepp; João B Calixto
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

6.  Comparative proteomics of cerebrospinal fluid reveals a predictive model for differential diagnosis of pneumococcal, meningococcal, and enteroviral meningitis, and novel putative therapeutic targets.

Authors:  Ana Paula Cordeiro; Rosiane Aparecida Silva Pereira; Alex Chapeaurouge; Clarice Semião Coimbra; Jonas Perales; Guilherme Oliveira; Talitah Michel Sanchez Candiani; Roney Santos Coimbra
Journal:  BMC Genomics       Date:  2015-05-26       Impact factor: 3.969

7.  Vasoinhibins regulate the inner and outer blood-retinal barrier and limit retinal oxidative stress.

Authors:  David Arredondo Zamarripa; Nundehui Díaz-Lezama; Rodrigo Meléndez García; Jesús Chávez Balderas; Norma Adán; Maria G Ledesma-Colunga; Edith Arnold; Carmen Clapp; Stéphanie Thebault
Journal:  Front Cell Neurosci       Date:  2014-10-20       Impact factor: 5.505

8.  Autoimmune diabetes is suppressed by treatment with recombinant human tissue Kallikrein-1.

Authors:  Lilia Maneva-Radicheva; Christina Amatya; Camille Parker; Jacob Ellefson; Ilian Radichev; Arvind Raghavan; Matthew L Charles; Mark S Williams; Mark S Robbins; Alexei Y Savinov
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

9.  Neuroprotective effect of kinin B1 receptor activation in acute cerebral ischemia in diabetic mice.

Authors:  Dorinne Desposito; Georges Zadigue; Christopher Taveau; Clovis Adam; François Alhenc-Gelas; Nadine Bouby; Ronan Roussel
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

10.  Relation of plasma tissue kallikrein levels to presence and severity of coronary artery disease in a Chinese population.

Authors:  Qin Zhang; Xiao Ran; Dao Wen Wang
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.